(Q33340278)

English

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens (English)

1 reference

Europe PubMed Central

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

10

object named as

H P Kalofonos

0 references

author name string

C Kosmas

1

1 reference

Europe PubMed Central

25 July 2017

N Tsavaris

2

1 reference

Europe PubMed Central

25 July 2017

M Vadiaka

3

1 reference

Europe PubMed Central

25 July 2017

N Stavroyianni

4

1 reference

Europe PubMed Central

25 July 2017

A Koutras

5

1 reference

Europe PubMed Central

25 July 2017

N Malamos

6

1 reference

Europe PubMed Central

25 July 2017

A Onyenadum

7

1 reference

Europe PubMed Central

25 July 2017

S Rokana

8

1 reference

Europe PubMed Central

25 July 2017

A Polyzos

9

1 reference

Europe PubMed Central

25 July 2017

H P Kalofonos

10

1 reference

Europe PubMed Central

25 July 2017

language of work or name

0 references

publication date

1 December 2001

1 reference

Europe PubMed Central

25 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

25 July 2017

92

1 reference

Europe PubMed Central

25 July 2017

11

1 reference

Europe PubMed Central

25 July 2017

2902-2910

1 reference

Europe PubMed Central

25 July 2017

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011201%2992%3A11%3C2902%3A%3AAID-CNCR10103%3E3.0.CO%3B2-O

21 January 2018

Identifiers

10.1002/1097-0142(20011201)92:11<2902::AID-CNCR10103>3.0.CO;2-O

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33340278&oldid=1773390959"